Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety profile, and advancements in a central manufacturi...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/2/e008735.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861329827463168 |
|---|---|
| author | Sarah Nikiforow John Haanen Omid Hamid Igor Puzanov Rodabe Amaria Amod Sarnaik Marcus O Butler Michael R Bishop Allison Betof Warner Adam J Schoenfeld Krishna Komanduri |
| author_facet | Sarah Nikiforow John Haanen Omid Hamid Igor Puzanov Rodabe Amaria Amod Sarnaik Marcus O Butler Michael R Bishop Allison Betof Warner Adam J Schoenfeld Krishna Komanduri |
| author_sort | Sarah Nikiforow |
| collection | DOAJ |
| description | Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety profile, and advancements in a central manufacturing process, lifileucel is now the first US Food and Drug Administration (FDA)-approved TIL cell therapy product. To this end, treatment management and delivery practice guidance is needed to ensure successful integration of this modality into clinical care. This review includes clinical and toxicity management guidelines pertaining to the TIL cell therapy regimen prepared by the TIL Working Group, composed of internationally recognized hematologists and oncologists with expertize in TIL cell therapy, and relates to patient care and operational aspects. Expert consensus recommendations for patient management, including patient eligibility, screening tests, and clinical and toxicity management with TIL cell therapy, including tumor tissue procurement surgery, non-myeloablative lymphodepletion, TIL infusion, and IL-2 administration, are discussed in the context of potential standard of care TIL use. These recommendations provide practical guidelines for optimal clinical management during administration of the TIL cell therapy regimen, and recognition of subsequent management of toxicities. These guidelines are focused on multidisciplinary teams of physicians, nurses, and stakeholders involved in the care of these patients. |
| format | Article |
| id | doaj-art-4e07c2e8bb504c78877c9560e59a0a72 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-4e07c2e8bb504c78877c9560e59a0a722025-02-09T22:05:13ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-02-0112210.1136/jitc-2023-008735Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapySarah Nikiforow0John Haanen1Omid Hamid2Igor Puzanov3Rodabe Amaria4Amod Sarnaik5Marcus O Butler6Michael R Bishop7Allison Betof Warner8Adam J Schoenfeld9Krishna Komanduri107 Dana-Farber Cancer Institute, Boston, Massachusetts, USA6 Medical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands4The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, USA3Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA4 The University of Texas MD Anderson Cancer Center, Houston, Texas, USA10 H Lee Moffitt Canc Ctr, Tampa, Florida, USA2University Health Network, Toronto, ON, Canada11 The David and Etta Jonas Center for Cellular Therapy, Chicago, Illinois, USAStanford University School of Medicine, Stanford, California, USA1Memorial Sloan Kettering Cancer Center, New York, NY, USA3 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USAAdoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety profile, and advancements in a central manufacturing process, lifileucel is now the first US Food and Drug Administration (FDA)-approved TIL cell therapy product. To this end, treatment management and delivery practice guidance is needed to ensure successful integration of this modality into clinical care. This review includes clinical and toxicity management guidelines pertaining to the TIL cell therapy regimen prepared by the TIL Working Group, composed of internationally recognized hematologists and oncologists with expertize in TIL cell therapy, and relates to patient care and operational aspects. Expert consensus recommendations for patient management, including patient eligibility, screening tests, and clinical and toxicity management with TIL cell therapy, including tumor tissue procurement surgery, non-myeloablative lymphodepletion, TIL infusion, and IL-2 administration, are discussed in the context of potential standard of care TIL use. These recommendations provide practical guidelines for optimal clinical management during administration of the TIL cell therapy regimen, and recognition of subsequent management of toxicities. These guidelines are focused on multidisciplinary teams of physicians, nurses, and stakeholders involved in the care of these patients.https://jitc.bmj.com/content/12/2/e008735.full |
| spellingShingle | Sarah Nikiforow John Haanen Omid Hamid Igor Puzanov Rodabe Amaria Amod Sarnaik Marcus O Butler Michael R Bishop Allison Betof Warner Adam J Schoenfeld Krishna Komanduri Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy Journal for ImmunoTherapy of Cancer |
| title | Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy |
| title_full | Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy |
| title_fullStr | Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy |
| title_full_unstemmed | Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy |
| title_short | Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy |
| title_sort | expert consensus guidelines on management and best practices for tumor infiltrating lymphocyte cell therapy |
| url | https://jitc.bmj.com/content/12/2/e008735.full |
| work_keys_str_mv | AT sarahnikiforow expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT johnhaanen expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT omidhamid expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT igorpuzanov expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT rodabeamaria expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT amodsarnaik expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT marcusobutler expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT michaelrbishop expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT allisonbetofwarner expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT adamjschoenfeld expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy AT krishnakomanduri expertconsensusguidelinesonmanagementandbestpracticesfortumorinfiltratinglymphocytecelltherapy |